Cogstate Limited (COGZF) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Healthcare Information Services Branche. Der Hauptsitz des Unternehmens ist in Melbourne, VIC, Australia. Der aktuelle CEO ist Bradley John O'Connor.
COGZF hat IPO-Datum 2010-04-05, 147 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $258.2M.
Cogstate Limited, a neuroscience technology company, provides computerized cognitive tests and electronic clinical outcome assessment solutions. The company's cognitive services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. It operates in Clinical Trials and Healthcare segments. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Healthcare segment provides Cognigram, a system for regular and standardized testing to assist primary care physicians and/or hospitals in the early detection of cognitive decline. As of June 30, 2022, it had participated in approximately 1,800 academic research. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.
